Last reviewed · How we verify
Bupivacaine liposomal injectable suspension
Bupivacaine liposomal injectable suspension is a local anesthetic that blocks sodium channels in nerve cell membranes, with prolonged duration of action due to encapsulation in liposomes.
Bupivacaine liposomal injectable suspension is a local anesthetic that blocks sodium channels in nerve cell membranes, with prolonged duration of action due to encapsulation in liposomes. Used for Local anesthesia for infiltration, nerve block, and epidural anesthesia, Postoperative pain management.
At a glance
| Generic name | Bupivacaine liposomal injectable suspension |
|---|---|
| Also known as | Exparel® (Pacira Pharmacoceuticals) |
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | Local anesthetic (liposomal formulation) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Pain Management |
| Phase | FDA-approved |
Mechanism of action
Bupivacaine is an amide-type local anesthetic that inhibits sodium influx into nerve cells, preventing depolarization and conduction of nerve impulses. The liposomal formulation encapsulates bupivacaine in lipid vesicles, which provides sustained release of the drug and extends the duration of anesthesia compared to conventional bupivacaine solutions, reducing the need for repeated dosing.
Approved indications
- Local anesthesia for infiltration, nerve block, and epidural anesthesia
- Postoperative pain management
Common side effects
- Hypotension
- Bradycardia
- Nausea
- Headache
- Dizziness
- Systemic toxicity (CNS and cardiac effects at high doses)
Key clinical trials
- EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement (PHASE2)
- Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery (PHASE3)
- Efficacy of EXPAREL vs. Bupivacaine (PHASE3)
- Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain (PHASE2, PHASE3)
- Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy (PHASE2)
- Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial) (PHASE2)
- R.E.C.K vs Exparel in Robotic Nephrectomy (PHASE3)
- A Study of TLC590 for Postsurgical Pain Following Bunionectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: